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Abstract Endothelin-converting enzyme-1 (ECE-1) is a critical
enzyme in the biosynthesis of the potent vasoconstrictor peptide
endothelin and exists in several isoforms. Anti-peptide antibodies
raised against epitopes in the distinct N-terminal cytoplasmic
tails of the rat ECE-1 isoforms have been obtained. By using
these antibodies in Western blot analysis and immunofluores-
cence studies, we have shown that cultures of transformed rat
lung vascular endothelial cells treated with the metalloprotease
inhibitor phosphoramidon and untreated cells express ECE-1K
only, whereas human umbilical vein endothelial cells express
ECE-1K and ECE-1L. The ECE-1 isoforms expressed in CHO-
K1 cells transfected with rat cDNA to ECE-1K and ECE-1L
could be immunoprecipitated by using the appropriate isospecific
antibody.
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1. Introduction
The endothelins were ¢rst isolated from the supernatant of
cultured endothelial cells [1]. Endothelins 1, 2 and 3 (ET-1,
ET-2 and ET-3) are vasoactive peptides which are synthesised
from proprotein precursors via the constitutive secretory path-
way. Endothelin-converting enzyme (ECE) is unique to pro-
endothelin processing in endothelial, smooth muscle and other
cell types and its proteolytic action produces ET-1 from its
inactive intermediate peptide, big-ET-1. ECE is, therefore, a
potentially important therapeutic target for cardiovascular
and other diseases (for review see [2]).
ECE was ¢rst puri¢ed to homogeneity from rat lung [3].
Cloning of the rat, human and bovine cDNAs to ECE-1 rap-
idly followed [4^8]. The ECE-1 polypeptides from these spe-
cies were found to have a high sequence similarity to each
other, except at their extreme N-termini. The presence of
two isoforms of ECE-1 was recognised in rat and these were
termed ECE-1K and ECE-1L (and in human ECE-1b and
ECE-1a, respectively) according to their NH2-terminal se-
quences [9] [10]. The isoforms were found to be identical in
speci¢c activity and substrate speci¢city [9^11]. The two iso-
forms are encoded by the same gene and are generated
through the use of alternative promoters [10]. Although di¡er-
ences in the relative mRNA expression ratios of the ECE-1
isoforms have been detected, rat and human ECE-1K mRNA
was usually found to be the more abundant form in the var-
ious tissues and cells examined [9] [10]. In addition, an appar-
ent increase in ECE-1 protein levels, but not in ECE-1 mRNA
levels, by the ECE metalloprotease inhibitors phosphorami-
don and thiorphan has been noted previously [5] [12]. To date,
however, it has not been possible to measure the relative levels
of protein expression of the two isoforms. Although antibod-
ies which recognise the C-terminal domain of rat and human
ECE-1 have been used extensively in immunological studies
[12^14], these antibodies do not distinguish the ECE-1K and
ECE-1L proteins. We have now developed polyclonal anti-
bodies to the N-termini of ECE-1K and ECE-1L which are
able to distinguish immunologically between the two proteins.
We have exploited these antibodies to evaluate ECE-1 protein
expression in cell lines. The antibodies are suitable for use in
immuno£uorescence, Western blotting and immunoprecipita-
tion.
2. Materials and methods
2.1. Materials
CHO cells were obtained from the European Collection of Cell
Culture (Salisbury, Wiltshire, UK). Simian virus 40-transformed rat
lung vascular endothelial cells (TRLEC-03 cells) were donated by Dr.
S. Tsurufuji, Institute of Cytosignal Research, Tokyo, Japan, and
human umbilical vein endothelial cells (HUVEC) were obtained as
cryopreserved primary cultures from Clonetics, TCS Biologicals Ltd,
Buckingham, UK. Penicillin, streptomycin, non-essential amino acids,
foetal calf serum, trypsin/EDTA and transfection reagent (lipofect-
Amine) were purchased from Gibco-BRL (Paisley, UK). Glasgow
minimal essential medium, nucleosides and sodium pyruvate were
purchased from Sigma (Poole, Dorset, UK). The plasmid
pcDLSRK296/rECE (containing rat ECE-1K or ECE-1L) was a kind
gift from Dr. K. Tanzawa (Sankyo, Tokyo, Japan) [6]. Synthetic
peptides were purchased from Genosys Biotechnologies Inc., Texas.
Sulfo MBS and Sulfolink gel were obtained from Pierce (Rockford,
IL, USA). The ECL Western blotting kit was obtained from Amer-
sham International plc.
2.2. Antibody production
Peptides A (SYKRATLDEEDLC; ECE-1K), B (SLRPPQGLGLQ-
WSSC; ECE-1L) and C (CLGKKGPGLTVSLPL; ECE-1L) were
coupled via a C-terminal cysteine (peptides A and B) or an N-terminal
cysteine (peptide C) to ovalbumin using standard procedures (Fig. 1)
[15]. New Zealand White rabbits were immunised with the conjugated
peptides according to standard protocols [15]. A preimmune bleed was
taken from each rabbit before immunisation. 200 Wg of peptide was
injected initially and 100 Wg in subsequent injections every 4 weeks.
Sample bleeds were taken 7^10 days after each immunisation to ob-
tain the peak response. Serum was stored at 370‡C.
Speci¢city and sensitivity of antibody production was determined
by enzyme-linked immunosorbent assay (ELISA) using standard
methods [15]. The secondary antibody (anti-rabbit horseradish perox-
idase IgG) was diluted 1/1000. The substrate used was 2,2P-azino-
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bis(3-ethylbenzthiazoline-6-sulphonic acid) (ABTS) in 5.72 ml 0.1 M
citric acid, 4.27 ml 0.2 M Na2HPO4, 1 Wl 30% H2O2, pH 4.3. Assays
were also carried out in the absence of antisera and with preimmune
serum replacing antiserum. Speci¢city of the antisera was assayed by
binding to the appropriate opposing peptide.
Antibodies were puri¢ed by using an a⁄nity column prepared by
the attachment of the cysteine containing peptides to iodoacetyl-agar-
ose (Sulfolink) according to the manufacturer’s recommendations.
The speci¢c antibodies were eluted with diethylamine, pH 11, or gly-
cine-HCl, pH 2.4. Elution of the antibodies from the column was
con¢rmed by ELISA as described above.
2.3. Gel electrophoresis and blotting
SDS-PAGE sample bu¡er was added to the samples which were
then treated with 5% L-mercaptoethanol and subjected to SDS-PAGE
using a 7.5% resolving gel [12]. Western blotting was carried out by
using the Amersham enhanced chemiluminescence (ECL) kit and pro-
tocol. The puri¢ed anti-peptide antibodies against rat ECE-1K and
ECE-1L were diluted 1/500. The secondary antibody was the anti-
rabbit horseradish peroxidase conjugate (dilution 1/5000).
2.4. Cell culture
CHO-K1 cells were cultured in Glasgow minimal essential medium
containing 10% (v/v) foetal calf serum as described in [16]. TRLEC-03
cells were cultured in RPMI-1640 medium containing 10% (v/v) foetal
calf serum and HUVECs were grown in a supplemented endothelial
basal medium, according to the suppliers’ instructions. All cells were
grown in a humidi¢ed incubator in a 5% CO2 atmosphere at 37‡C.
Membrane fractions were prepared from cells as described previously
[17].
2.5. Immuno£uorescence
TRLEC-03, HUVEC and CHO-K1 cells were grown on coverslips
in 24-well plates. CHO-K1 cells were transiently transfected with rat
ECE-1K or ECE-1L [16] and the cells were ¢xed and stained 24^48 h
post-transfection. The TRLEC-03, HUVEC and CHO-K1 cells were
¢xed with methanol/acetone (1:1) and immunostained as in [12]. The
puri¢ed anti-peptide antibodies were diluted 1/50 (anti-ECE-1K ; AS-
66) or 1/100 (anti-ECE-1L ; AS-65). The secondary antibody was anti-
rabbit £uorescein isothiocyanate (FITC) (1/100).
2.6. Immunoprecipitation
A sample of a 1 mg/ml solubilised membrane preparation of ECE-
1K or ECE-1L transfected CHO cells was preincubated with protein A
(10% v/v) for 1 h at 4‡C with rotation, followed by centrifugation at
10 000Ug for 15 s at 4‡C. Preimmune serum (0.5 Wl) and each of the
anti-peptide antibodies were separately incubated with a 1 ml sample
of the supernatant for 1 h on ice. Protein A was then added to each
sample (10% v/v) and incubated for 1 h at 4‡C with rotation. The
beads were collected by centrifugation at 10 000Ug for 15 s at 4‡C
and washed with Tris-bu¡ered saline (50 mM Tris, 150 mM sodium
chloride, pH 7.4) containing 0.1% (v/v) Tween 20 (TBST). Sample
bu¡er (20 Wl) was added and the samples were heated to 85‡C for
10 min. After centrifugation (10 000Ug, 15 s, 4‡C), 1 Wl L- mercap-
toethanol was added to each supernatant which was then heated to
100‡C for 4 min. The samples were subjected to SDS-PAGE on a
7.5% gel as described previously and blotted using the ECL system.
The primary antibodies were diluted 1/500.
3. Results
3.1. ELISA
ELISA revealed that the antisera against peptides A, B and
C showed immunoreactivity with the corresponding peptides.
The antibodies AS-66 to ECE-1K (raised against peptide A)
and AS-65 to ECE-1L (raised against peptide C) showed the
greatest immune response, being 15^20 times that of the pre-
immune bleed. These two antisera were, therefore, chosen for
puri¢cation. The antiserum against peptide B showed a weak
response (2^3 times that of the preimmune serum) and was
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Fig. 1. Comparison of the N terminal sequences of ECE-1K and
ECE-1L of rat, human and bovine cDNA. Underlined regions indi-
cate the sequences in rat cDNA from which peptides were designed
to raise speci¢c anti-ECE-1K and anti-ECE-1L antibodies. ECE-1K :
peptide A, SYKRATLDEEDLC; ECE-1L : peptide B, SLRPPQGL-
GLQWSSC; ECE-1L : peptide C, CLGKKGPGLTVSLPL.
Fig. 2. Immunoblots of ECE-1K and ECE-1L expressed in CHO-K1
cells. a: Untransfected cells (lanes 1 and 2, 7 and 8), ECE-1K trans-
fected cells (lanes 3 and 4, 9 and 10) and ECE-1L transfected cells
(lanes 5 and 6, 11 and 12) were blotted with AS-66 to ECE-1K (K)
and AS-65 to ECE-1L (L). Lanes 1, 3, 5, 7, 9 and 11 were loaded
with 6 Wg of protein. Lanes 2, 4, 6, 8, 10 and 12 were loaded with
10 Wg of protein. b: Immunoblots of ECE-1 in TRLEC-03 and HU-
VEC cells. Lanes 1 and 5 were loaded with 15 Wg of protein from
untreated TRLEC-03 cells. Lanes 2 and 6 were loaded with 15 Wg
of protein from TRLEC-03 cells treated with phosphoramidon
(PR). Lane 4 was loaded with 10 Wg of protein from ECE-1L trans-
fected CHO cells. Lanes 3 and 7 were loaded with 10 Wg of protein
from HUVEC membranes. The samples were blotted with AS-66 to
ECE-1K (K) and AS-65 to ECE-1L (L).
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therefore not puri¢ed or characterised further. Serial dilutions
of each antiserum were evaluated by ELISA and the relevant
dilution appropriate for subsequent studies was determined
(results not shown).
3.2. Western blotting
CHO cells were transfected with either rat ECE-1K or ECE-
1L cDNA. Western blotting of membranes prepared from
these cells, using the puri¢ed antisera AS-66 and AS-65, re-
vealed that each antiserum recognised the corresponding pro-
tein speci¢cally (Fig. 2a, lanes 3 and 4, 11 and 12). No cross-
reactivity was observed with untransfected CHO cells (Fig. 2a,
lanes 1 and 2, 7 and 8) or with CHO cells expressing the
opposing ECE-1K or ECE-1L protein (Fig. 2a, lanes 5 and
6, 9 and 10).
Immunoblotting of TRLEC-03 membranes indicated the
presence of ECE-1K at an Mr of 120 000 (Fig. 2b, lane 1),
the level of which was increased approximately 3-fold (as
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Fig. 3. Immuno£uorescent microscopy of ECE-1 using isoform-speci¢c antibodies. Immuno£uorescence of ECE-1K transfected CHO cells (a
and b), ECE-1L transfected CHO cells (c and d), TRLEC-03 cells (e and f) and HUVEC cells (g and h) was carried out by using AS-66 to
ECE-1K (left-hand panel) and AS-65 to ECE-1L (right-hand panel). For details see Section 2.
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quanti¢ed by densitometry (Scanmaster 3, Howtek)) following
treatment of the cells with phosphoramidon (Fig. 2b, lane 2).
Although ECE-1L was not detected in the TRLEC-03 mem-
branes (Fig. 2b, lanes 5 and 6), membranes from CHO cells
transfected with rat ECE-1L were immunopositive for this
isoform (Fig. 2b, lane 4) with a similar Mr. By way of con-
trast, in HUVEC membranes both isoforms were present,
ECE-1L (Fig. 2b, lane 7) being more abundant than ECE-
1K (Fig. 2b, lane 3). The antibodies, although designed against
the rat sequences, are therefore suitable for detection of the
corresponding human ECE-1 isoforms. The lower immunore-
active band (Mr 97 000) seen in each lane has been observed
previously in HUVECs when using the monoclonal antibody
AEC 32-236 and its presence is probably due to proteolysis
[7,12].
3.3. Immuno£uorescence
CHO-K1 cells transiently transfected with rat ECE-1K or
ECE-1L, TRLEC-03 cells and HUVEC cells were analysed by
immuno£uorescent microscopy using the isoform speci¢c anti-
bodies AS-66 (Fig. 3, left-hand panel) and AS-65 (Fig. 3,
right-hand panel). Staining was observed when CHO cells
expressing ECE-1K or ECE-1L were incubated with their cor-
responding antibody (Fig. 3a,d, respectively). By way of con-
trast, ECE-1K or ECE-1L transfected CHO cells showed no
staining when incubated with the opposing antibodies (Fig.
3b,c, respectively). In transfected CHO cells, ECE-1K and
ECE-1L both showed a predominantly plasma membrane lo-
cation, as did the ECE-1K detected in TRLEC-03 cells.
As with the Western blots, staining was apparent in
TRLEC-03 cells incubated with the ECE-1K antibody, but
no staining was seen with the ECE-1L antibody in these cells
(Fig. 3e,f). Staining of both isoforms was revealed in HUVEC
cells incubated with either AS-66 or AS-65 (Fig. 3g,h).
3.4. Immunoprecipitation
The antibodies AS-66 and AS-65 were incubated with solu-
bilised membranes from CHO cells transfected with their re-
spective ECE-1 isoform cDNAs on ice for 1 h. Immunopre-
cipitation was then carried out by binding of the immune
complexes to protein A. Preimmune serum replaced the anti-
serum in one sample as a control. SDS-PAGE of these sam-
ples followed by Western blotting for ECE-1, using the iso-
form-speci¢c antibodies as the primary antibodies in each
case, revealed that both antibodies immunoprecipitated the
relevant corresponding protein (Fig. 4, lanes 2 and 4). No
ECE-1 was detected in the control samples where preimmune
serum replaced the anti-peptide antibodies (Fig. 4, lanes 1 and
3).
4. Discussion
In this study, we describe for the ¢rst time the production
and characterisation of polyclonal antibodies raised to pep-
tides contained within the N-terminal cytoplasmic domains of
the ECE-1K and ECE-1L isoforms. Immuno£uorescence stud-
ies and Western blot analysis of ECE-1 expressed in CHO-K1
cells demonstrate that the antibodies AS-66 and AS-65 stain
speci¢cally the ECE-1K and ECE-1L proteins, respectively.
Previously described monoclonal antibodies raised to ECE-1
[13] recognise epitopes in the C-terminal domain and therefore
bind both isoforms. As these monoclonal antibodies are un-
able to discriminate between the proteins, determination of
the distribution and expression levels of the isoforms in var-
ious tissues and cells has not previously been possible.
Here, we demonstrate for the ¢rst time, by immuno£uo-
rescence and Western blot analysis, the protein expression of
both ECE-1 isoforms in HUVEC cells and also establish that
only the ECE-1K isoform is expressed in TRLEC-03 cells.
Previous observations have shown an increase in the level of
ECE-1 following treatment of TRLEC-03 cells with metallo-
protease inhibitors, especially phosphoramidon [5,12]. How-
ever, at that time, the existence of ECE-1 isoforms was not
recognised. This increased level of ECE-1 has now been un-
equivocally identi¢ed as the K isoform with the novel isospe-
ci¢c antibodies.
The level of isoform expression may be of signi¢cance in
di¡erent pathological states and this variation in protein ex-
pression could be used as an indicator of disease progression
and/or e⁄cacy of therapeutic intervention. For example, the
increase in level of ECE-1 following balloon injuries in rat
carotid arteries, used as a model for human atherosclerotic
lesions [18], could be a re£ection of an increase in both or
only one of the isoforms. The availability of isoform-speci¢c
antibodies could therefore be of value in such clinical inves-
tigations. Relative expression levels of the ECE-1 mRNAs
may also be a¡ected by cell transformation. For example, it
is possible that the transformation of rat lung endothelial cells
with SV-40 DNA resulted in down-regulation of ECE-1L
mRNA, thus explaining the detection of ECE-1K only in
this cell line. Since ECE-1K and ECE-1L have di¡erent tissue
distributions and expression levels, this may be a re£ection of
distinct physiological roles.
In contrast to the monoclonal antibodies to ECE-1 pro-
duced previously which did not immunoprecipitate the corre-
sponding protein [13], immunoprecipitation of the respective
ECE-1 isoforms is possible using the polyclonal antibodies
AS-66 and AS-65. These antibodies could be useful for further
characterisation of ECE-1, determination of the distribution
of the isoforms both at the subcellular level in cells and in
tissues, and in the clari¢cation of the role of the ECE-1 iso-
forms in various pathological states.
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Fig. 4. Immunoprecipitation of ECE-1 by the isoform-speci¢c anti-
ECE antibodies. Solubilised membranes from CHO cells transfected
with the respective rat ECE-1 isoform cDNAs were incubated with
the relevant antibody. The antibody complex was then immunopre-
cipitated by treatment with protein A. In one sample, preimmune
serum was used as a control. Lanes 1 and 3 show treatment with
the preimmune serum and lanes 2 and 4 show immunoprecipitation
of ECE-1K and ECE-1L by AS-66 and AS-65, respectively.
C.D. Brown et al./FEBS Letters 424 (1998) 183^187186
References
[1] Yanagisawa, M., Kurihara, H., Kimura, S., Tomobe, Y., Ko-
bayashi, M., Mitsui, Y., Yazaki, Y., Goto, K. and Masaki, T.
(1988) Nature 332, 411^415.
[2] Turner, A.J. and Tanzawa, K. (1997) FASEB J. 11, 355^364.
[3] Takahashi, M., Matsushita, Y., Iijima, Y. and Tanzawa, K.
(1993) J. Biol. Chem. 268, 21394^21398.
[4] Ikura, T., Sawamura, T., Shiraki, T., Hosokawa, H., Kido, T.,
Hoshikawa, H., Shimada, K., Tanzawa, K., Kobayashi, S.,
Miwa, S. and Masaki, T. (1994) Biochem. Biophys. Res. Com-
mun. 203, 1417^1422.
[5] Schmidt, M., Kroger, B., Jacob, E., Seulberger, H., Subkowski,
T., Otter, R., Meyer, T., Schmalzing, G. and Hillen, H. (1994)
FEBS Lett. 356, 238^243.
[6] Shimada, K., Takahashi, M. and Tanzawa, K. (1994) J. Biol.
Chem. 269, 18275^18278.
[7] Shimada, K., Matsushita, Y., Wakabayashi, K., Takahashi, M.,
Matsubara, A., Iijima, Y. and Tanzawa, K. (1995) Biochem.
Biophys. Res. Commun. 207, 807^812.
[8] Xu, D., Emoto, N., Giaid, A., Slaughter, C., Kaw, S., deWit, D.
and Yanagisawa, M. (1994) Cell 78, 473^485.
[9] Shimada, K., Takahashi, M., Ikeda, M. and Tanzawa, K. (1995)
FEBS Lett. 371, 140^144.
[10] Valdenaire, O., Rohrbacher, E. and Mattei, M.-G. (1995) J. Biol.
Chem. 270, 29794^29798.
[11] Turner, A.J. and Murphy, L.J. (1996) Biochem. Pharmacol. 51,
91^102.
[12] Barnes, K., Shimada, K., Takahashi, M., Tanzawa, K. and Turn-
er, A.J. (1996) J. Cell Sci. 109, 919^928.
[13] Takahashi, M., Fukuda, K., Shimada, K., Barnes, K., Turner,
A.J., Ikeda, M., Koike, H., Yamamoto, Y. and Tanzawa, K.
(1995) Biochem. J. 311, 657^665.
[14] Barnes, K., Brown, C. and Turner, A.J. (1998) Hypertension 31
(in press).
[15] Baldwin, S.A. (1994) in: Methods in Molecular Biology (Higgins,
J.M.G.a.J.A., Ed.), Vol. 27, pp. 43^63, Humana Press, Totowa,
NJ.
[16] Hoang, M.V. and Turner, A.J. (1997) Biochem. J. 327, 23^26.
[17] Barnes, L., Murphy, L.J., Takahashi, M., Tanzawa, K. and
Turner, A.J. (1995) J. Cardiovasc. Pharmacol. 26, S37^S39.
[18] Wang, X., Douglas, S.A., Louden, C., Vickery-Clark, L.M.,
Feuerstein, G.Z. and Ohlstein, E.H. (1996) Circ. Res. 78, 322^
328.
FEBS 19919 11-3-98
C.D. Brown et al./FEBS Letters 424 (1998) 183^187 187
